Uveal melanoma is the most common primary intraocular malignancy in adults. And there is an absence of targeted agents for patients with uveal melanoma. Pyrvinium pamoate is an old anthelminthic medicine approved by FDA for the treatment of enterobiasis in 1955, which recently reattracts attention as an anti-cancer drug due to its inhibition of Wnt/β-catenin pathway in some types of cancer. But the role of pyrvinium pamoate in uveal melanoma and the potential underlying mechanism remains unknown. In this study, we tested the anti-tumor effects of pyrvinium pamoate on four uveal melanoma cell lines (92.1, Mel270, Omm1, and Omm2.3) and evaluated the Wnt/β-catenin signaling transduction, cell growth, cell death, cell migration, and invasion accordingly. The results revealed that pyrvinium pamoate treatment repressed the phosphorylation of GSK3β at S9 which might be mediated by AKT, and decreased the protein levels of β-catenin and its downstream targets (c-Myc, cyclin D1). Pyrvinium pamoate remarkably inhibited cell viability and colony formation ability. Treatment with pyrvinium pamoate induced intrinsic pathway-dependent apoptosis accompanied with a decline of anti-apoptotic XIAP and Survivin, and an overt increase of pro-apoptotic Bax. In addition, pyrvinium pamoate significantly inhibited the migration and invasion in vitro. Our studies suggest that pyrvinium pamoate may be a potential therapeutic agent for uveal melanoma.
Introduction
Uveal melanoma is the most common primary intraocular malignancy in adults, which consists of iris, ciliary body and choroidal melanomas. The annual incidence is 4-7 cases per million in the USA [1, 2] . Despite the development of many treatment options applicable for uveal melanoma in the past 30 years, the event-free survival has remained constant which is most commonly attributed to metastatic disease [3] .
Conventional systemic chemotherapy shows limited effectiveness in metastatic uveal melanoma, which is caused by a poor understanding of therapeutic targets. Contrary to cutaneous melanoma, v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) or neuroblastoma rat sarcoma viral oncogene homolog (NRAS) mutations are rare in patients with uveal melanoma [4] . Although mutated guanine nucleotide binding protein (G protein) subunit αq (GNAQ) and subunit α11 (GNA11) play a crucial role in the development of uveal melanoma, there are no specific GNAQ and GNA11 inhibitors available in clinic [5] [6] [7] [8] . Therefore, it is extremely important to identify potential new therapeutic target drugs for uveal melanoma.
Aberrant activity of Wnt/β-catenin signaling has been implicated in various tumors, such as cervical cancer [9] , gastric cancer [10] , intestinal cancer [11] , lung cancer [12] , human cutaneous melanoma [13] , and uveal melanoma [14] . Zuidervaart et al. [14] showed that Wnt5a and β-catenin were increased in primary uveal melanoma, which was associated with poorer prognosis in patients. Furthermore, Chang et al. [15] identified that β-catenin is a biomarker for Class 2 signature which is potently correlated with metastatic uveal melanoma.
Pyrvinium pamoate is an old anthelminthic medicine approved by FDA for treatment of enterobiasis in 1955. It disturbs glucose absorption and suppresses the NADH-fumarate reductase system of parasitic helminthes, thereby inhibiting ATP production and killing the parasite [16] . However, because of the low absorption across the gastrointestinal tract of pyrvinium pamoate, this drug has been discontinued for the treatment of intestinal parasites in the USA. Recently, pyrvinium pamoate re-attracts attention as an anti-cancer drug because of its potent activity against colon cancer cell, myeloma cell, and breast cancer cell [17] [18] [19] .
Due to the strong inhibitory effect of pyrvinium pamoate on Wnt/β-catenin pathway in aforementioned cancer cells, we hypothesized that pyrvinium pamoate might possess anti-tumor activity through blocking Wnt/β-catenin signaling in uveal melanoma cell. In this study, we tested this hypothesis and demonstrated that pyrvinium pamoate decreased the viability of uveal melanoma cells in vitro. Our studies suggest that pyrvinium pamoate may be a potential new therapeutic agent for uveal melanoma.
Materials and Methods

Reagents and antibodies
Pyrvinium pamoate (chemical structure, Fig. 1A ) was purchased from Sigma-Aldrich (St Louis, USA) and prepared as a 20 mM stocking solution in dimethyl sulfoxide (DMSO) and stored in aliquots at −20°C. Antibodies and their sources were as follows: antibodies against poly (ADP)-ribose polymerase (PARP; clone 4C10-5), Bcl-2, X-linked inhibitor of apoptosis (XIAP), active caspase-3 and cytochrome c (clone 6H2.B4), survivin, and c-terminal β-catenin were from BD Biosciences (San Jose, USA). Antibodies against Bax, Bcl-X L , GSK3β (H-76), and cyclin D1 (C-20) were from Santa Cruz Biotechnology (Santa Cruz, USA). Antibodies against β-actin, α-tubulin, caspase-3, -9, phospho-GSK3β at S9, c-Myc, matrix metalloproteinase (MMP)-2 and -9 were from Cell Signaling Technology (Beverly, USA). Fluorescent-conjugated anti-mouse immunoglobulin G and anti-rabbit immunoglobulin G secondary antibodies were from LI-COR Biotechnology (Lincoln, USA).
Cell culture
The uveal melanoma cells of 92.1, Mel270, Omm1, and Omm2.3 were provided by Dr. Jager MJ of Leiden University Medical Center (Leiden, the Netherlands). Cell line 92.1 was derived from a primary uveal melanoma with orbit infiltration [20] . Cell line Mel270 was isolated from a ciliary body melanoma, which received failed plaque therapy before excision [21] . Cell line Omm1 was isolated from a subcutaneous metastatic lesion, which was derived from a uveal melanoma with enucleation 29 years earlier [22] . Cell line Omm2.3 was isolated from hepatic metastases, which is derived from the same patient of cell line Mel270 [20] . Human adult retinal pigmented epithelium (ARPE-19) cells were purchased from ATCC (Manassas, USA). The uveal melanoma cells were cultured in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum (FBS), L-glutamine (2 mM), HEPES buffer (10 mM), sodium pyruvate (1 mM), 50 IU/ml penicillin and 50 μg/ml streptomycin [23, 24] . ARPE-19 cells were cultured in DMEM/F12 culture medium supplemented with 10% FBS. All cells were incubated at 37°C in a humidified incubator containing 5% CO 2 [25] .
Immunofluorescence staining
The 92.1 cells were cultured on uncoated glass slides for 24 h, and then treated with 1.0 μM pyrvinium pamoate for another 24 h. Subsequently, the cells were washed with PBS (3 × 5 min), fixed with 4% paraformaldehyde for 15 min, permeabilized with 1% Triton X-100 and 0.5% NP-40 for 20 min. After being washed with PBS (3 × 5 min), the cells were blocked with 1% bovine serum albumin (BSA), incubated overnight at 4°C with the primary antibody, washed with PBS (3 × 5 min), and then incubated with DyLight 488 conjugatedgoat-anti-mouse antibodies (Pierce Biotechnology, Rockford, USA) for 1 h at room temperature. After extensive wash with PBS, cell nucleus was counterstained with DAPI. All slides were examined under a microscope with high magnification (400×). 
Dual-luciferase reporter assay
Western blot analysis
Whole cell lysates were prepared with radioimmunoprecipitation assay (RIPA) buffer (1 × PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 0.1 mg/ml phenylmethanesulfonyl fluoride, 20 mM sodium fluoride, 0.2 mM sodium orthovanadate, and complete protease inhibitor mix, one tablet per 50 ml) [23, 24, 27] . Cytoplasmic and nuclear fractionations were prepared as follow: pyrvinium pamoate-treated cells were pelleted by centrifugation and washed with PBS. Pellets were then resuspended in 200 μl ice-cold lysis buffer (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.4% NP-40 with 1 mM DTT, 0.5 mM PMSF, 1 mM sodium orthovanadate and Complete Protease Inhibitor Mix). After incubation on ice for 10 min, the lysates were centrifuged at 10,000 g. The supernatants were saved as cytoplasmic fractions. After being washed with the lysis buffer, the pellets were vigorously resuspended in nuclear protein extraction buffer (20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA with 1 mM DTT, 0.5 mM PMSF, 0.2 mM sodium orthovanadate and Complete Protease Inhibitor Mix) and centrifuged at 14,000 g for 10 min at 4°C. The supernatants were collected as nuclear fractions and frozen at −80°C [23, 24, 27] . Protein samples were separated on SDS-PAGE gel and transferred to nitrocellulose membranes which were then incubated with the primary antibodies. After incubation with the appropriate secondary antibodies, the immunoblots were analyzed by LICOROdyssey infra-red scanner (LI-COR Biotechnology).
Soft agar clonogenic assay
After 24 h of treatment with pyrvinium pamoate, or diluent (DMSO as control), the uveal melanoma cells were harvested, washed, and seeded in drug-free double layer culture system for colony formation. In brief, a lower layer of 1.0% agarose (Invitrogen, Carlsbad, USA) containing 1 ml of RPMI 1640 medium and 10% FBS was initially solidified in a 24-well culture plate. Three thousands uveal melanoma cells in 0.5% agarose were seeded on the lower layer. Triplicate parallel wells were used for each treatment concentration. After incubation at 37°C with 5% CO 2 atmosphere for 10-14 days, colonies were counted by using an inverted phase-contrast microscope (200×) as described previously [23, 24, 27] .
Wound-healing assay
The 92.1 cells (2 × 10 5 /well) were seeded in 6-well plates and cultured to confluence. A vertical wound was created using a 200-μl pipette tip. The plates were washed three times with PBS and Figure 1 . Pyrvinium pamoate inhibits Wnt/β-catenin signaling (A) Chemical structure of pyrvinium pamoate (PP). (B) Pyrvinium pamoate decreased β-catenin and its downstream targets. Uveal melanoma cells were exposed to increasing concentrations of pyrvinium pamoate for 24 h. Whole cell lysates were subject to western blot analysis with the indicated antibodies, respectively. (C) Pyrvinium pamoate concentration-dependently lowered β-catenin. The 92.1 cells were incubated with pyrvinium pamoate for 24 h, cytoplasmic and nuclear extracts were analyzed by immunoblotting. (D) The 92.1 cells were pretreated with 1.0 μM pyrvinium pamoate for 24 h, immunofluorescence analysis was performed with anti-β-catenin. Nuclei were stained with DAPI. (E) Pyrvinium pamoate abrogated TCF/LEF-dependent luciferase activity. After transfected with TOPflash and FOPflash plasmids and pEFRenilla-luc, 92.1 cells were treated with 0, 0.5, 1.0, and 2.0 μM of pyrvinium pamoate for 24 h. Luciferase activity was detected using a dual-luciferase assay. n = 3; *P < 0.05; **P < 0.01; ***P < 0.001, compared with the control.
replaced with fresh RPMI 1640 medium containing different concentrations of pyrvinium pamoate (0, 0.125, 0.25, or 0.5 μM). Wound breadth was observed and photographed using an inverted microscope. Image J software was used to quantitatively analyze the wound breadth. The inhibition effectiveness of pyrvinium pamoate was estimated by the relative breadth of wound closure.
In vitro transwell migration and invasion assay 
Statistical analysis
All experiments were performed at least three times, and data are expressed as the mean ± standard deviation (SD) unless otherwise stated. GraphPad Prism 5.0 software (GraphPad Software, San Diego, USA) was used for statistical analysis. Comparisons among multiple groups involved one-way ANOVA with post hoc intergroup comparison with the Tukey test. P < 0.05 was considered statistically significant.
Results
Pyrvinium pamoate inhibits Wnt/β-catenin pathway in uveal melanoma cells
Given that pyrvinium pamoate is an inhibitor of Wnt/β-catenin pathway in diverse types of cancer (e.g. colon cancer, myeloma, and breast cancer) cells [17] [18] [19] , we first examined whether pyrvinium pamoate is active against Wnt/β-catenin pathway in uveal melanoma cells. To this end, two lines of uveal melanoma cells were exposed to pyrvinium pamoate, western blot analysis showed a dose-dependent decrease in the total levels of β-catenin and its downstream targets (e.g. c-Myc, cyclin D1) in pyrvinium pamoate-treated cells (Fig. 1B) .
Because nuclear translocation of β-catenin is required for executing its functions, we next examined whether pyrvinium pamoate affects the subcellular distribution of β-catenin. The results showed that pyrvinium pamoate significantly reduced β-catenin in both cytoplasmic and nuclear fractionations (Fig. 1C) . Immunofluorescence analysis further confirmed that β-catenin was lowered by pyrvinium pamoate in both cytosolic and nuclear compartments (Fig. 1D) . Moreover, a dual-luciferase assay was used to evaluate this effect of pyrvinium pamoate on the T-cell specific transcription factor (TCF)/ lymphoid enhancer-binding factor (LEF) transcriptional function. Pyrvinium pamoate significantly inhibited the luciferase activity of TOP promoter constructs with optimized TCF-binding sites in a dose-dependent manner compared to control cells (Fig. 1E) .
GSK3β acts as a critical upstream regulator of β-catenin in the canonical Wnt/β-catenin pathway, we next investigated the effect of pyrvinium pamoate on GSK3β. Pyrvinium pamoate treatment in uveal melanoma cells significantly increased the phospho-β-catenin (S33/37, T41; Fig. 2A) , which may reflect an increased activity of GSK3β on β-catenin. Furthermore, it was also found that pyrvinium pamoate lowered the phospho-GSK3β at S9 without changing its phosphorylation at Y216 and total GSK3β protein ( Fig. 2A) . Quantitative analysis of phospho-GSK3β (S9) showed that pyrvinium pamoate treatment in uveal melanoma cells decreased phospho-GSK3β (S9) in a concentration-dependent manner with EC 50 values ranged from 0.9 to 3.8 μM (data not shown). Because AKT phosphorylates GSK3β (S9) [28] , we next evaluated the impact of pyrvinium pamoate on AKT. Consistent with GSK3β (S9), a striking decrease in p-AKT was detected in the pyrvinium pamoate-treated cells (Fig. 2A) . A model of the effect of pyrvinium pamoate on Wnt/ β-catenin pathway was shown in Fig. 2B .
Pyrvinium pamoate inhibits growth of uveal melanoma cells
We next determined the effect of pyrvinium pamoate on the growth of uveal melanoma cells. Four lines of uveal melanoma cells were exposed to increasing concentrations of pyrvinium pamoate for 72 h. Cell viability was measured by the MTS assay. The results showed that pyrvinium pamoate significantly inhibited the growth of 92.1, Mel270, Omm1, and Omm2.3 cells, with IC 50 values of these cells being 2.67 μM (92.1), 5.0 μM (Mel270), 4.9 μM (Omm1), and 5.7 μM (Omm2.3), respectively (Fig. 3A) . In order to distinguish an inhibitory effect of pyrvinium pamoate from a toxic effect, we also examined the effects of pyrvinium pamoate on Figure 2 . The underlying mechanism involved in the effect of pyrvinium pamoate on Wnt/β-catenin pathway (A) Uveal melanoma cells were exposed to increasing concentrations of pyrvinium pamoate for 24 h. Lysates were prepared as indicated and subject to western blot analysis. (B) A model of the effect of pyrvinium pamoate on Wnt/β-catenin pathway. Inhibition of Wnt signaling by pyrvinium pamoate may be due to the suppression of phosphorylation of AKT and GSK3β (S9), and thus to promote the degradation of β-catenin.
normal human ocular cells ARPE-19. Pyrvinium pamoate (∼10 μM) did not significantly decrease the cell viability of ARPE-19 cells when treated for 72 h (Fig. 3A) . Additionally, trypan blue exclusion assay was used to further assess the toxic effect of pyrvinium pamoate on ARPE-19 cell. The results showed that pyrvinium pamoate at ∼10 μM (maximum concentration) did not exert any significant cytotoxic activity against ARPE-19 cells (data not shown). These results may suggest that pyrvinium pamoate may exert an inhibitory effect rather than a toxic effect on uveal melanoma cells.
Of interest, we compared the effect of pyrvinium pamoate in the presence of 10% FBS versus 1% FBS in 92.1 and Omm1 cells. After treatment, cell viability was detected by MTS assay. Similar sensitivity was seen in 92.1 and Omm1 cells when cells were cultured with pyrvinium pamoate under these two high and low concentrations of serum (data not shown), which suggested that serum might not significantly reduce the efficacy of pyrvinium pamoate.
Because clonogenicity can better reflect malignant behavior of tumor cells, we therefore determined the effect of pyrvinium pamoate on clonogenicity in uveal melanoma cells. The uveal melanoma cells were exposed to increasing concentrations of pyrvinium pamoate for 24 h, then washed and seeded in drug-free colony formation culture medium for 10-14 days. The results revealed that pyrvinium pamoate inhibited the colony formation in a concentrationdependent manner (Fig. 3B) .
Pyrvinium pamoate induces apoptosis in uveal melanoma cells by triggering the mitochondrial apoptosis pathway
We next assessed the ability for pyrvinium pamoate to induce cell death by the trypan blue exclusion assay. The results showed that pyrvinium pamoate treatment led to a concentration-and time-dependent cell death in the four lines of uveal melanoma cells (Fig. 4A) .
Because pyrvinium pamoate itself possessed color which strongly interfered with the fluorescence of fluorescein isothiocyanate (FITC) and phycoerythrin (PE), we failed to evaluate apoptosis by flow cytometry with Annexin V-FITC and PE. We therefore used immunoblotting to assess apoptosis by monitoring specific cleavage of PARP and caspase-3 which are hallmarks of apoptosis [29] . As shown in Fig. 4B , pyrvinium pamoate induced specific cleavage of PARP and caspase-3 activation in a concentration-and timedependent manner in all four uveal melanoma cell lines, suggesting that pyrvinium pamoate efficiently induced apoptotic cell death in uveal melanoma cells.
The release of cytochrome c from mitochondria into the cytosol is an indicator of cell apoptosis in the early phase [30] . We therefore monitored the levels of cytochrome c in the cytosol of pyrvinium pamoate-treated cells. Western blot analysis of the cytosolic fractionations extracted with digitonin buffer revealed that the cytochrome c was not detectable in control cells, but was progressively elevated after pyrvinium pamoate treatment (Fig. 4C) , suggesting that pyrvinium pamoate induced apoptosis in uveal melanoma cells through an intrinsic pathway.
To further explore the mechanism by which pyrvinium pamoate induces apoptosis, we examined the expressions of apoptosis-related proteins. Western blot analysis in all tested uveal melanoma cells revealed a prominent decrease in protein levels of anti-apoptotic XIAP and survivin in a dose-and time-dependent manner, but an obvious increase in pro-apoptotic protein Bax (Fig. 5A,B) . However, there was no alteration in the levels of Bcl-2 and Bcl-X L (Fig. 5A,B) . 
Pyrvinium pamoate suppresses migration and invasion of uveal melanoma cells
Metastasis is a major cause of mortality for uveal melanoma [31, 32] . Moreover, Wnt/β-catenin signaling has been identified as a key regulator in metastasis of uveal melanoma [14, 15] . Thus, we next evaluated the effect of pyrvinium pamoate on the migration and invasion of uveal melanoma cells by wound-healing assay, transwell migration and invasion assay, respectively. The results indicated that pyrvinium pamoate significantly inhibited the migration and invasion of uveal melanoma cells (Fig. 6A-C) .
Immunoblot assay also showed a dose-dependent decrease of MMP-9 and MMP-2 in pyrvinium pamoate-treated cells (Fig. 6D) .
Discussion
Uveal melanoma is a primary intraocular tumor which can be fatal in adults. Despite the advance in local ocular treatments, effective target-based therapies for uveal melanoma are still lacking. In the present study, we discovered that pyrvinium pamoate potently suppressed Wnt/β-catenin signaling, cellular survival, migration and invasion of uveal melanoma cells. Our data suggest that pyrvinium pamoate may be a potential agent for treatment of uveal melanoma.
Our results showed that pyrvinium pamoate inhibited β-catenin and its downstream targets (e.g. c-Myc, cyclin D1) in uveal melanoma cells. Pyrvinium pamoate may exert its inhibitory effect on Wnt/β-catenin pathway at multiple layers. (i) Pyrvinium pamoate treatment elicits a decrease in the phospho-GSK3β at S9 and an increase in the phospho-β-catenin (S33/37, T41) in uveal melanoma cells. Phosphorylation of β-catenin on GSK3β sites (S33/37, T41) is a prerequisite step for the ubiquitin-mediated degradation of β-catenin. The increase in phosphorylation of β-catenin on GSK3β sites (S33/37, T41) may be explained because the decreased phospho-GSK3β at S9 could elevate the activity of GSK3β. Regarding the underlying mechanism, we found that pyrvinium pamoate inhibits the phosphorylation of AKT, which is responsible for GSK3β phosphorylation at S9. (ii) Pyrvinium pamoate may inhibit Wnt signaling by activating casein kinase 1α, which decreases the stabilization of β-catenin and increases the levels of Axin in colorectal carcinoma cells [33] . (iii) In lung cancer cells, pyrvinium pamoate treatment decreases the transcriptional expression of several key upstream components of Wnt/GSK3β, e.g. Wnt7b, frizzled-1 and low density lipoprotein receptor-related protein-5 [34] .We found that pyrvinium pamoate, a FDA-approved anthelmintic drug, can strongly suppress the uveal melanoma cells proliferation without harming normal cells. The downstream effectors of Wnt/β-catenin signaling have been demonstrated to be the key regulators for tumor progression, such as c-myc and cyclin D1, which can promote rapid proliferation by driving the cell cycle [35, 36] . C-myc activates the transcription of many critical positive cell cycle regulators (e.g. cyclins, E2F transcription factors), represses the activity of cell cycle inhibitor (p21, p27) and thus stimulates the proliferative effects [35] . Moreover, cyclin D1 acts as a regulator of cyclin-dependent kinase 4 (CDK4) and CDK6 to promote cell cycle transition from G1 to S phase. Over-expression of cyclin D1 leads to cell growth and tumor progression [36] . Our study revealed that pyrvinium pamoate treatment reduced the expression of c-Myc and cyclin D1.
The underlying mechanism of the differential sensitivities to pyrvinium pamoate in the different lines of uveal melanoma cells is not clear at present, and remains to be elucidated in the future work. It can probably be attributed to the different genetic background of these UM cells. For example, 92.1 cells has mutation of eukaryotic translation initiation factor 1A (EIF1AX) gene which is associated with good prognosis in uveal melanoma [1] . Furthermore, the inhibition of proliferation conferred by off-target effect may not be excluded because it has been reported that pyrvinium pamoate can block janus kinase-2 (JAK-2)/signal transducer and activator of transcription-5 (STAT-5) in tumor cells [37] .
Pyrvinium pamoate obviously induces apoptosis in uveal melanoma by triggering the mitochondrial pathway. Our data demonstrated that pyrvinium pamoate down-regulated pro-survival effector proteins of XIAP and survivin, and increased the proapoptotic effector proteins of Bax. Bax has been identified as regulatory factors in the release of cytochrome c. Furthermore, XIAP and survivin function as endogenous inhibitors of caspases, including caspase-3, caspase-7, and caspase-9 [38] . The anti-apoptotic Bcl-2 proteins (Bcl-2 and Bcl-X L ) are not affected by pyrvinium pamoate. This may suggest that the fate of uveal melanoma cells treated by pyrvinium pamoate may be determined by the ratio of Bcl-2 to Bax. Upregulation of Bax counteracts the death repressor activity of Bcl-2 [39] .
Moreover, we found that pyrvinium pamoate exhibits potent inhibitory effect on migration and invasion of uveal melanoma cells. Approximately 40%-50% of patients with primary uveal melanoma will ultimately develop distant metastasis and lack effective antimetastasis agents [2] . In this study, pyrvinium pamoate was confirmed to down-regulate the expression of MMPs, which can promote tumor invasion and metastasis through degrading the extracellular matrix. Therefore, pyrvinium pamoate may be used as an alternative agent for treating patients with metastatic melanoma of the eye; however, its suppression effect on metastasis in vivo will be explored in future research. In summary, we validated that pyrvinium pamoate inhibits growth, migration, and invasion of uveal melanoma cells with the blockage of signal transduction and downstream targets (c-Myc, cyclin D1, Survivin, and MMPs) in Wnt/β-catenin pathway. Because pyrvinium pamoate is an FDA-approved drug, a clinical trial of this drug in uveal melanoma may be warranted. Of note, pyrvinium pamoate is difficult to be absorbed. A single oral dose (250 mg) of pyrvinium pamoate suspension in healthy individuals was shown to provoke a maximum plasma level of only 7.4 ng/ml (12.9 nM) pyrvinium [40] , which may not be sufficient to give rise to an inhibitory effect. To make pyrvinium pamoate applicable in patients with cancer, novel delivery strategies should be developed to increase its absorption efficieny through further pharmacokinetics and pharmacodynamics studies. 
